Nitric oxide, caveolae, and vascular pathology

Cardiovascular Toxicology

Volumn 6, Issue 1, 2006, Pages 1-13

  Li, Xiang An ^a   Everson, William ^a   Smart, Eric J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AMP kinase; CD36; Diabetes; Endothelial nitric oxide synthase; eNOS; Scavenger receptor BI

Indexed keywords

ADENYLATE KINASE; ANTIDIABETIC AGENT; CASPASE; CAVEOLIN 1; CD36 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; METFORMIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR BI; SULFONYLUREA DERIVATIVE;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CAVEOLA; CYTOTOXICITY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DNA CLEAVAGE; ENDOTHELIUM CELL; ENERGY YIELD; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAVEOLAE; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION;

EID: 33746424427     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:6:1:1     Document Type: Review

References (78)

1. Shaul, P.W., Smart, E.J., Robinson, L.J., et al. (1996). Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 271:6518-6522.
2. Couet, J., Li, S., Okamoto, T., Ikezu, T., and Lisanti, M.P. (1997). Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272:6525-6533.
3. Garcia-Cardena, G., Martasek, P., Masters, B.S., et al. (1997). Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J. Biol. Chem. 272:25,437-25,440.
4. Minshall, R.D., Sessa, W.C., Stan, R.V., Anderson, R.G., and Malik, A.B. (2003). Caveolin regulation of endothelial function. Am. J. Physiol. Lung Cell Mol. Physiol. 285:L1179-1183.
5. Smart, E.J., Graf, G.A., McNiven, M.A., et al. (1999). Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell Biol. 19:7289-7304.
6. Bernatchez, P.N., Bauer, P.M., Yu, J., Prendergast, J.S., He, P., and Sessa, W.C. (2005). Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc. Natl. Acad. Sci. USA 102:761-766.
7. Ju, H., Zou, R., Venema, V.J., and Venema, R.C. (1997). Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 272:18,522-18,525.
8. Ou, J., Fontana, J.T., Ou, Z., et al. (2004). Heat shock protein 90 and tyrosine kinase regulate eNOS NO* generation but not NO* bioactivity. Am. J. Physiol. Heart Circ. Physiol. 286:H561-569.
9. Sessa, W.C. (2004). eNOS at a glance. J. Cell Sci. 117:2427-2429.
10. Shaul, P.W. (2002). Regulation of endothelial nitric oxide synthase: location, location, location. Ann. Rev. Physiol. 64:749-774.
11. Shaul, P.W. (2003). Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J. Physiol. 547:21-33.
12. Blair, A., Shaul, P.W., Yuhanna, I.S., Conrad, P.A., and Smart, E.J. (1999). Oxidized low density lipoprotein displaces endothelial nitric oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J. Biol. Chem. 274:32,512-32,519.
13. Rothberg, K.G., Heuser, J.E., Donzell, W.C., Ying, Y., Glenney, J.R., and Anderson, R.G.W. (1992). Caveolin, a protein component of caveolae membrane coats. Cell 68:673-682.
14. Rothberg, K.G., Ying, Y., Kamen, B.A., and Anderson, R.G.W. (1990). Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J. Cell Biol. 111:2931-2938.
15. Smart, E.J., Ying, Y., Donzell, W.C., and Anderson, R.G. ( 1996). A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J. Biol. Chem. 271:29,427-29,435.
16. Smart, E.J., Ying, Y.-Y., Conrad, P.A., and Anderson, R.G.W. (1994). Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J. Cell Biol. 127:1185-1197.
17. Febbraio, M., Hajjar, D.P., and Silverstein, R.L. (2001). CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108:785-791.
18. Nicholson, A.C. (2002). Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc. Med. 14:8-12.
19. Krieger, M. (1999). Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Ann. Rev. Biochem. 68:523-558.
20. Krieger, M. (2001). Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J. Clin. Invest. 108:793-797.
21. Uittenbogaard, A., Shaul, P.W., Yuhanna, I.S., Blair, A., and Smart, E.J. (2000). High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275:11,278-11,283.
22. Graf, G.A., Connell, P.M., van der Westhuyzen, D.R., and Smart, E.J. (1999). The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J. Biol. Chem. 274:12,043-12,048.
23. Yuhanna, I.S., Zhu, Y., Cox, B.E., et al. (2001). High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:853-857.
24. Li, X.-A., Titlow, W.B., Jackson, B.A., et al. (2002). High-density lipoprotein binding to scavenger receptor class B, type I activates endothelial nitric oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 277:11,058-11,063.
25. Mineo, C., Yuhanna, I.S., Quon, M.J., and Shaul, P.W. (2003). High density lipoprotein-induced endothelial nitricoxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278:9142-9149.
26. Brunner, F., Maier, R., Andrew, P., Wolkart, G., Zechner, R., and Mayer, B. (2003). Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc. Res. 57:55-62.
27. Braun, A., Trigatti, B.L., Post, M.J., et al. (2002). Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90:270-276.
28. Tall, A.R. (2002). Mighty mouse. Circ. Res. 90:244-245.
29. Ueda, Y., Gong, E., Royer, L., Cooper, P.N., Francone, O.L., and Rubin, E.M. (2000). Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J. Biol. Chem. 275:20,368-20,373.
30. Williams, S.J., Hemmings, D.G., Mitchell, J.M., McMillen, I.C., and Davidge, S.T. (2005). Effects of maternal hypoxia or nutrient restriction during pregnancy on endothelial function in adult male rat offspring. J. Physiol. 565:125-135.
31. Li, X.A., Guo, L., Dressman, J.L., Asmis, R., and Smart, E.J. (2005). A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein. J. Biol. Chem. 280:19,087-19,096.
32. Fomenko, D.E. and Gladyshev, V.N. (2002). CxxS: fold-independent redox motif revealed by genome-wide searches for thiol/disulfide oxidoreductase function. Protein Sci. 11:2285-2296.
33. Khosravi-Far, R. and Esposti, M.D. (2004). Death receptor signals to mitochondria. Cancer Biol. Ther. 3:1051-1057.
34. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. (1999). Biochemical pathways of caspase activation during apoptosis. Ann. Rev. Cell Dev. Biol. 15:269-290.
35. Hengartner, M.O. (2000). The biochemistry of apoptosis. Nature 407:770-776.
36. Kotamraju, S., Hogg, N., Joseph, J., Keefer, L.K., and Kalyanaraman, B. (2001). Inhibition of oxidized low-density lipoprotein-induced apoptosis in endothelial cells by nitric oxide. Peroxyl radical scavenging as an antiapoptotic mechanism. J. Biol. Chem. 276:17,316-17,323.
37. Ross, R. (1999). Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115-126.
38. Ferrara, N., Carver-Moore, K., Chen, H., et al. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
39. Fong, G.H., Rossant, J., Gertsenstein, M., and Breitman, M.L. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
40. Kliche, S. and Waltenberger, J. (2001). VEGF receptor signaling and endothelial function. IUBMB Life 52:61-66.
41. Xu, W., Liu, L.Z., Loizidou, M., Ahmed, M., and Charles, I.G. (2002). The role of nitric oxide in cancer. Cell Res. 12:311-320.
42. Zachary, I. and Gliki, G. (2001). Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49:568-581.
43. Koshida, R., Ou, J., Matsunaga, T., et al. (2003). Angiostatin: a negative regulator of endothelial-dependent vasodilation. Circulation 107:803-806.
44. Urbich, C., Reissner, A., Chavakis, E., et al. (2002). Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 16:706-708.
45. Hegardt, P., Widegren, B., Li, L., et al. (2001). Nitric oxide synthase inhibitor and IL-18 enhance the antitumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol. Immunother. 50:491-501.
46. Uneda, S., Hata, H., Matsuno, F., et al. (2003). A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br. J. Haematol. 120:396-404.
47. Lee, P.C., Salyapongse, A.N., Bragdon, G.A., et al. (1999). Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol. 277:H1600-1608.
48. Kawashima, S. and Yokoyama, M. (2004). Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:998-1005.
49. Mueller, C.F., Laude, K., McNally, J.S., and Harrison, D.G. (2005). ATVB in focus: redox mechanisms in blood vessels. Arterioscler. Thromb. Vasc. Biol. 25:274-278.
50. Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625.
51. Son, S.M., Whalin, M.K., Harrison, D.G., Taylor, W.R., and Griendling, K.K. (2004). Oxidative stress and diabetic vascular complications. Curr. Diab. Rep. 4:247-252.
52. Silverstein, R.L. and Febbraio, M. (2000). CD36 and atherosclerosis. Curr. Opin. Lipidol. 11:483-491.
53. Stremmel, W., Pohl, J., Ring, A., and Herrmann, T. (2001). A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 36:981-989.
54. Zhang, X., Fitzsimmons, R.L., Cleland, L.G., et al. (2003). CD36/fatty acid translocase in rats: distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-BI. Lab. Invest. 83:317-332.
55. Febbraio, M., Abumrad, N.A., Hajjar, D.P., et al. (1999). A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274:19,055-19,062.
56. Pohl, J., Ring, A., Korkmaz, U., Ehehalt, R., and Stremmel, W. (2004). FAT/CD36 mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts. Mol. Biol. Cell 16:24-31.
57. Irie, H., Krukenkamp, I.B., Brinkmann, J.F., et al. (2003). Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids. Proc. Natl. Acad. Sci. USA 100:6819-6824.
58. Kuang, M., Febbraio, M., Wagg, C., Lopaschuk, G.D., and Dyck, J.R. (2004). Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109:1550-1557.
59. Hardie, D.G. (2004). AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med. Sci. Sports Exerc. 36:28-34.
60. Marrow, V.A., Foufelle, F., Connell, J.M.C., Petrie, J.R., Gould, G.W., and Salt, I.P. (2003). Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J. Biol. Chem. 278:31,629-31,639.
61. Mitchelhill, K.I., Stapleton, D., Gao, G., et al. (1994). Mammalian AMP-activated protein kinase shares structural and functional homology with the catalytic domain of yeast Snfl protein kinase. J. Biol. Chem. 269:2361-2364.
62. Stapleton, D., Mitchelhill, K.I., Gao, G., et al. (1996). Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 12:611-614.
63. Stapleton, D., Woollatt, E., Mitchelhill, K.I., et al. (1997). AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett. 409:452-456.
64. Carling, D. (2004). The AMP-activated protein kinase cascade - unifying system for energy control. Trends Biochem. Sci. 29:18-24.
65. Zou, M.H., Hou, X.Y., Shi, C.M., et al. (2003). Activation of 5′-AMP-activated kinase is mediated through c-src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. J. Biol. Chem. 278:34,003-34,010.
66. Zou, M.H., Hou, X.Y., Shi, C.M., Nagata, D., Walsh, K., and Cohen, R.A. (2002). Modulation by peroxynitrite of akt- and AMP-activated kinase-dependent ser1179 phosphorylation of endothelial nitric oxide synthase. J. Biol. Chem. 277:32,552-32,557.
67. Hawley, S.A., Gadalla, A.E., Olsen, G.S., and Hardie, D.G. (2002). The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420-2425.
68. Esenabhalu, V.E., Schaeffer, G., and Graier, W.F. (2003). Free fatty acid overload attenuates Ca2+ signaling and NO production in endothelial cells. Antioxid. Redox. Signal 5:147-153.
69. Zhu, W. and Smart, E.J. (2005). Myristic acid stimulates endothelial nitric-oxide synthase in a CD36- and an AMP kinase-dependent manner. J. Biol. Chem. 280:29,543-29,550.
70. Olefsky, J.M. and Saltiel, A.R. (2000). PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 11:362-368.
71. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M., and Kliewer, S.A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:12,953-12,956.
72. Wu, Z., Xie, Y., Morrison, R.F., Bucher, N.L., and Farmer, S.R. (1998). PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101:22-32.
73. Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., and Evans, R.M. (1995). 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803-812.
74. Tontonoz, P., Singer, S., Forman, B.M., et al. (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94:237-241.
75. Gribble, F.M. and Ashcroft, F.M. (2000). Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 49:3-6.
76. Fukuen, S., Iwaki, M., Yasui, A., Makishima, M., Matsuda, M., and Shimomura, I. (2005). Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J. Biol. Chem. 280:23,653-23,659.
77. Zhou, G., Myers, R., Li, Y., et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174.
78. Zou, M.H., Kirkpatick, S.S., Davis, B.J., et al. (2004). Activation of the AMP-activated protein kinase by the antidiabetic drug metformin in vivo. J. Biol. Chem. 279:43,940-43,951.